UT 311 PAH Study

Study Description: Subjects are being asked to be in this research study who recently completed the TDE-PH-310 study. The purpose of this research study is to assess how an investigational drug called UT-15C (treprostinil diethanolamine also known as treprostinil diolamine) works to treat PA. The study will continue for four years. Subject visits will occur at Baseline, Weeks 6, 12, and every 12weeks thereafter.

Contact for Enrollment

     (706) 721-0193

    Submit Information Online

Principal Investigator: Clark McDonough

Eligibility Criteria:

Compensation: Yes, subjects will be compensated.

Compensation Explanation: There is no direct payment for participating in this study. Some payment may be provided for travel related expenses required for study participation (e.g., parking fees).


Didn't find a study to participate in?

If you don't see specific studies that interest you, please submit your contact information for future studies.